Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Use of SYNJARDY for this indication is supported by evidence from a 26-week double-blind, placebo-controlled clinical trial of empagliflozin, with a double-blind active treatment safety extension period of up to 52 weeks in 157 pediatric patients aged 10 to 17 years with type 2 diabetes mellitus and a pediatric pharmacokinetic study [see Clinical Pharmacology (12.3) and Clinical Studies (14.2)]
Int J Radiat Oncol Biol Phys
Q: Who is this product for
An alternative line of investigation has focused on using immune cells as direct antifibrotic mediators
US$ 26.48
US$ 26.61
US$ 24.65
US$ 24.98
US$ 29.37
US$ 20.50
